Abstract | OBJECTIVES: METHODS: Patients with stage IB-1 to IVA untreated primary cervix cancers were eligible for enrollment into this study. Carboplatin was administered on a weekly basis with external radiation therapy (ERT). Low-dose brachytherapy was given after completion of ERT. Acute toxicities and response to treatment were assessed. RESULTS: Thirty-one evaluable patients were enrolled. The majority of patients had early stage disease. Carboplatin was successfully administered in 175 out of 186 (94%) planned treatments. All patients completed the prescribed course of radiation therapy. The mean treatment time was 50 days (36-73). There were no treatment delays for neutropenia or gastrointestinal toxicity. No patient was hospitalized for treatment related toxicities. Gastrointestinal toxicity equivalent to grade 3 or 4 was not reported. The objective tumor response based on physical exam findings and computed tomography measurements was 90%. CONCLUSION:
|
Authors | Robert V Higgins, Wendel R Naumann, James B Hall, Michael Haake |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 89
Issue 3
Pg. 499-503
(Jun 2003)
ISSN: 0090-8258 [Print] United States |
PMID | 12798718
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Carboplatin
|
Topics |
- Adenocarcinoma
(drug therapy, radiotherapy)
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Brachytherapy
(adverse effects, methods)
- Carboplatin
(therapeutic use)
- Carcinoma, Adenosquamous
(drug therapy, radiotherapy)
- Carcinoma, Squamous Cell
(drug therapy, radiotherapy)
- Combined Modality Therapy
(adverse effects)
- Female
- Humans
- Neoplasm Staging
- Radiotherapy
(adverse effects)
- Uterine Cervical Neoplasms
(drug therapy, radiotherapy)
|